Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.78 EUR | +0.30% | +9.71% | +2.11% |
14/05 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
25/04 | Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.11% | 345M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.67% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Top Premarket Gainers